Bloom Science Granted Exclusive Option to License Gut Microbiome-based Therapies for ALS, Other Neurological Disorders
Bloom Science and Duke University have entered into an exclusive licensing agreement that provides the biopharmaceutical company access to the intellectual property and technology related to unique strain isolates and genetic variants of Akkermansia genus bacteria. This type of…
SeaSpine® Announces Exclusive Development and Licensing Agreement with restor3D®
September 24, 2019 CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it…
Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND for a Brain Cancer Vaccine
Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). ITI-1000 is currently being investigated in a Phase 2 ATTAC-II…
Exclusive License Agreement for Duke start-up, restor3D®
Ken Gall’s 3D-printing company, restor3D, has signed an exclusive license with SeaSpine, a global medical tech company. SeaSpine Holdings Corporation (SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal…
“Deep Sepsis” Licensed to Cohere Med
Cohere Med licenses technology from Duke to drive adoption of early Sepsis detection using AI PRESS RELEASE: 3 JULY 2019 Sepsis strikes more than a million Americans every year and 15 to 30 percent…
Enzyvant Announces FDA Acceptance of Biologics License Application
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia CAMBRIDGE, Mass. & BASEL, Switzerland–(BUSINESS WIRE)–Enzyvant, a biopharmaceutical company focused…
Enzyvant: FDA Acceptance of Biologics License Application
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia —RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform…
Showcasing Innovation at 2nd “Invented at Duke” Celebration
From Antiperspirant Lotion To Waste Treatment To Targeted Radiotherapy – Duke Made Yet Another Exhibition Of Ingenious Innovations That Span Numerous Fields And Applications. Riding on the success of the first “Invented at Duke” event…
Duke Celebrates Innovation & Entrepreneurship at 1st Annual “Invented at Duke”
“Commercialization turns discovery into invention, enabling Duke researchers to fulfill our institution’s mission of bringing knowledge to bear in service to society.” –President Price A puncture-proof vascular graft, silicone microspheres, improved eye disease imaging, a…